Refining the treatment of follicular lymphoma

References

• Liu Q, Fayad L, Cabanillas F, Hagemeister F B, Ayers G D, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582–1589
   PubMed Web of Science ®Google Scholar
• Fisher R I, LeBlanc M, Press O W, Maloney D G, Unger J M, Miller T P. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447–8452
   PubMed Web of Science ®Google Scholar
• van Oers M H. Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica 2007; 92: 826–833
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J O, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Foussard C, Mounier N, Van Hoof A, Delwail V, Casasnovas O, Deconinck E, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol 2006; 24: 7508, (Abstract)
   Google Scholar
• Herold M, Haas A, Srock S, Neser S, Al-Ali K H, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986–1992
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504–1508
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Fuller L M, Velasquez W S, Sullivan-Halley J A, Butler J J, Cabanillas F. Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer 1986; 58: 1596–1602
   PubMed Web of Science ®Google Scholar
• Besa P C, McLaughlin P W, Cox J D, Fuller L M. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer 1995; 75: 2361–2367
   PubMed Web of Science ®Google Scholar
• Plancarte F, Lopez-Guillermo A, Arenillas L, Montoto S, Gine E, Muntanola A, et al. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 2006; 76: 58–63
   PubMed Web of Science ®Google Scholar
• Seymour J F, Pro B, Fuller L M, Manning J T, Hagemeister F B, Romaguera J, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 2115–2122
   PubMed Web of Science ®Google Scholar
• Damaj G, Verkarre V, Delmer A, Solal-Celigny P, Yakoub-Agha I, Cellier C, et al. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol 2003; 14: 623–629
   PubMed Web of Science ®Google Scholar
• Goodlad J R, Krajewski A S, Batstone P J, McKay P, White J M, Benton E C, et al. Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am J Surg Pathol 2002; 26: 733–741
   PubMed Web of Science ®Google Scholar
• Zelenetz A D, Advani R H, Glenn M J, Bociek R G, Buadi F, Caligiuri M A, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma V3, Available at: http://www.nccn.org
   Google Scholar
• Guadagnolo B A, Li S, Neuberg D, Ng A, Hua L, Silver B, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64: 928–934
   PubMed Web of Science ®Google Scholar
• MacManus M P, Hoppe R T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282–1290
   PubMed Web of Science ®Google Scholar
• Petersen P M, Gospodarowicz M, Tsang R, Pintilie M, Wells W, Hodgson D, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation. J Clin Oncol 2004; 22: 6521, (Abstract)
   Google Scholar
• Soubeyran P, Eghbali H, Trojani M, Bonichon F, Richaud P, Hoerni B. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol 1996; 7: 713–718
   PubMed Web of Science ®Google Scholar
• Tezcan H, Vose J M, Bast M, Bierman P J, Kessinger A, Armitage J O. Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience. Leuk Lymphoma 1999; 34: 273–285
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France 2001
   Google Scholar
• Winter J N, Gascoyne R D, Van B K. Low-grade lymphoma. Hematology Am Soc Hematol Educ Program. 2004; 203–220
   Google Scholar
• Ganti A K, Weisenburger D D, Smith L M, Hans C P, Bociek R G, Bierman P J, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 2006; 17: 920–927
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Vose J M, Hock L M, Lynch J C, Aoun P, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101: 2363–2367
   PubMed Web of Science ®Google Scholar
• Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A, et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 1994; 84: 1043–1049
   PubMed Web of Science ®Google Scholar
• Weisenburger D D, Anderson J R, Diebold J, MacLennan K A, Muller-Hermelink H K, et al. Grading of follicular lymphoma: diagnostic accuracy, reproducibility and clinical relevance. Mod Pathol 1998; 11: 142, (Abstract)
   Google Scholar
• Wendum D, Sebban C, Gaulard P, Coiffier B, Tilly H, Cazals D, et al. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1654–1663
   PubMed Web of Science ®Google Scholar
• Rodriguez J, McLaughlin P, Hagemeister F B, Fayad L, Rodriguez M A, Santiago M, et al. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 1999; 93: 2202–2207
   PubMed Web of Science ®Google Scholar
• Krishnan A, Nademanee A, Fung H, Angelopoulou M, Molina A, Gaal K, et al. Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?. Biol Blood Marrow Transplant 2006; 12: 641–647
   PubMed Web of Science ®Google Scholar
• Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong S A, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351–365
   PubMed Web of Science ®Google Scholar
• Del Gaizo Moore V, Brown J R, Certo M, Love T M, Novina C D, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112–121
   PubMed Web of Science ®Google Scholar
• Deng J, Carlson N, Takeyama K, Dal C P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171–185
   PubMed Web of Science ®Google Scholar
• Mason K D, Carpinelli M R, Fletcher J I, Collinge J E, Hilton A A, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173–1186
   PubMed Web of Science ®Google Scholar
• Nakayama K, Nakayama K, Negishi I, Kuida K, Sawa H, Loh D Y. Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci USA 1994; 91: 3700–3704
   PubMed Web of Science ®Google Scholar
• Print C G, Loveland K L, Gibson L, Meehan T, Stylianou A, Wreford N, et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA 1998; 95: 12424–12431
   PubMed Web of Science ®Google Scholar
• Wagner K U, Claudio E, Rucker EB I II, Riedlinger G, Broussard C, Schwartzberg P L, et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 2000; 127: 4949–4958
   PubMed Web of Science ®Google Scholar
• Wilson W H, Tulpule A, Levine A M, Dunleavy K, Krivoshik A P, Hagey A E, et al. A phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Blood 2007; 110: 1371, (Abstract)
   Google Scholar
• Dave S S, Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W C, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169
   PubMed Web of Science ®Google Scholar
• de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23: 6358–6363
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado M T, Lopez C, Jaen J, Bosch R, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 5350–5357
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Camacho F I, Salvado M T, Sanchez L, Garcia J F, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006; 91: 1605–1612
   PubMed Web of Science ®Google Scholar
• Cerhan J R, Wang S, Maurer M J, Ansell S M, Geyer S M, Cozen W, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007; 109: 5439–5446
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider B F, Shumansky K, Spinelli J J, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169–2174
   PubMed Web of Science ®Google Scholar
• Lee A M, Clear A J, Calaminici M, Davies A J, Jordan S, MacDougall F, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24: 5052–5059
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox B C, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108: 2957–2964
   PubMed Web of Science ®Google Scholar
• Farinha P, Han J, Al-Tourah A, Connors J M, Banerjee D, Gascoyne R. The tumor microenvironment measured by flow cytometry predicts overall survival (OS) and transformation risk (TR) in follicular lymphoma. Blood 2006; 108: 2406, (Abstract)
   Google Scholar
• Glas A M, Knoops L, Delahaye L, Kersten M J, Kibbelaar R E, Wessels L A, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25: 390–398
   PubMed Web of Science ®Google Scholar
• Ai W YZ, Czerwinski D, Horning S J, Allen J, Tibshirani R, Levy R. Tumor-infiltrating T cells are not predictive of clinical outcome in follicular lymphoma. Blood 2006; 108: 824, (Abstract)
   Google Scholar
• Wahlin B E, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007; 13: 388–397
   PubMed Web of Science ®Google Scholar
• Yang Z Z, Novak A J, Ziesmer S C, Witzig T E, Ansell S M. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006; 66: 10145–10152
   PubMed Web of Science ®Google Scholar
• Horning S J. Durable remissions in stage III follicular lymphoma: interpret with caution. J Clin Oncol 1987; 5: 838–839
   PubMed Web of Science ®Google Scholar
• Anderson J R, Vose J M, Bierman P J, Weisenberger D D, Sanger W G, Pierson J, et al. Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. J Clin Oncol 1993; 11: 218–224
   PubMed Web of Science ®Google Scholar
• Bartlett N L, Rizeq M, Dorfman R F, Halpern J, Horning S J. Follicular large-cell lymphoma: intermediate or low grade?. J Clin Oncol 1994; 12: 1349–1357
   PubMed Web of Science ®Google Scholar
• Miller T P, LeBlanc M, Grogan T M, Fisher R I. Follicular lymphomas: do histologic subtypes predict outcome?. Hematol Oncol Clin North Am 1997; 11: 893–900
   PubMed Web of Science ®Google Scholar
• Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez M A, et al. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol 2000; 11: 1551–1556
   PubMed Web of Science ®Google Scholar
• Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman A R, et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. Br J Cancer 2003; 89: 36–42
   PubMed Web of Science ®Google Scholar